KN026 plus HB1801 for HER2-positive advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and sign a consent form to join.
- Your breast cancer must be confirmed as HER2-positive from a recent tissue/cell sample checked by a central lab.
- The cancer must be recurrent or metastatic (coming back or spread), confirmed with pathology (tissue) and/or cytology (cell testing).
- You should not have had chemotherapy or HER2-targeted treatment for the recurrent or metastatic breast cancer yet.
- Your health status should be ECOG 0–1 (able to do most daily activities).
- You need at least one measurable tumor spot on scans using RECIST 1.1, and your blood/organ function must be adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests KN026 together with chemotherapy in people with HER2-positive advanced stomach (or gastro-esophageal junction) cancer that has already grown despite first-line treatment with trastuzumab plus chemotherapy. It may help by targeting HER2 while also using chemotherapy to control the cancer.
This trial tests a new combination of drugs (KN026 plus chemotherapy, with or without KN-046) for people with HER2-positive colorectal or bile duct cancer that has spread. The goal is to see if this treatment can help shrink or control the cancer.
This study tests a new drug called KM257 for people with advanced solid tumors that have a high level of a protein called HER2. The drug is given as an infusion and is designed to target cancer cells with this protein, potentially slowing or stopping tumor growth.
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
This study tests a new combination of targeted therapies (HB1801 with trastuzumab and pertuzumab) plus chemotherapy for people with HER2-positive breast cancer that has spread or come back. It aims to see if this treatment helps shrink tumors or slow their growth.
This trial compares a new drug called JSKN003 with the standard combination of pertuzumab, trastuzumab, and docetaxel for people with HER2-positive breast cancer that has spread or returned. It aims to see if JSKN003 works as well as or better than the current standard first-line treatment.
Hear when a new First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.